Table 2. . Recipient characteristics for African–American and European–American recipients.
| Characteristics | European–American (n = 1560) | African–American (n = 363) | p-value |
|---|---|---|---|
| Age group (years), n (%) | <0.0001 | ||
| – 18–34 | 180 (11.5%) | 71 (19.6%) | |
| – 35–64 | 1121 (71.9%) | 272 (74.9%) | |
| – 65–84 | 259 (16.6%) | 20 (5.5%) | |
| Donor age group (years), n (%) | <0.0001 | ||
| – 0–34 | 485 (31.1%) | 171 (47.1%) | |
| – 35–64 | 1031 (66.1%) | 184 (50.7%) | |
| – 65–84 | 44 (2.8%) | 8 (2.2%) | |
| Living donor status, n (%) | 1031 (66.1%) | 112 (30.9%) | <0.0001 |
| Female, n (%) | 579 (37.1%) | 132 (36.4%) | 0.81 |
| Diabetes at transplant, n (%) | 611 (39.2%) | 133 (36.6%) | 0.40 |
| SPK, n (%) | 130 (8.3%) | 18 (5.0%) | 0.029 |
| Body mass index, mean (SD) | 28.3 (5.5) | 28.8 (5.4) | 0.075 |
| Antibody induction, n (%) | <0.0001 | ||
| – Monoclonal | 595 (38.1%) | 176 (48.5%) | |
| – Polyclonal | 857 (54.9%) | 175 (48.2%) | |
| – None | 63 (4.0%) | 6 (1.7%) | |
| – Combination | 45 (2.9%) | 6 (1.7%) | |
| Median tacrolimus trough (IQR) in the first 34 days in ng/ml | 8.7 (6.6–10.8) | 5.4 (3.5–7.9) | <0.0001 |
| Median tacrolimus trough (IQR) after day 34 in ng/ml | 8.1 (6.5–9.9) | 7.1 (5.4–9.0) | <0.0001 |
| Median daily tacrolimus dose (IQR) in first 24 days in mg | 6.0 (4.0–8.0) | 6.0 (4.0–8.0) | 0.77 |
| Median daily tacrolimus dose (IQR) after day 25 in mg | 5.0 (3.5–8.0) | 8.0 (6.0–10.0) | <0.0001 |
| Median dose-normalized tacrolimus trough (IQR) in ng/ml per total daily dose in mg | 1.52 (1.00–2.33) | 0.78 (0.52–1.22) | <0.0001 |
IQR: Interquartile range; SD: Standard deviation.